Baseline characteristics of study population during acute hantavirus infection; CRP C-reactive protein; LDH Lactate dehydrogenase; # Clinical signs and symptoms and laboratory values were taken at time of admission to hospital.

<p>Baseline characteristics of study population during acute hantavirus infection; CRP C-reactive protein; LDH Lactate dehydrogenase; # Clinical signs and symptoms and laboratory values were taken at time of admission to hospital.</p

In vitro susceptibility to empirical intraperitoneal treatment.

<p>A. Gram-positive organisms; B. Gram-negative organisms; P1, period 1 (1979–1992), n = 120 episodes; P2, period 2 (1993–2003), n = 125 episodes; P3, period 3 (2004–2014), n = 242 episodes; all variables are expressed as percentage.</p

Gram-positive organisms causing Peritoneal Dialysis-Related Peritonitis and their <i>In Vitro</i> Susceptibility Rates over 32 years.

<p>P1 = (1979–1992); P2 = period 2 (1993–2003); P3 = period 3 (2004–2014); number of antibiograms; percentage of full susceptibility; NT, not tested; Amp/Sulb, ampicillin/sulbactam,</p><p>*comparison between period 1 and period 3; NS, not significant;</p><p>Gram-positive organisms causing Peritoneal Dialysis-Related Peritonitis and their <i>In Vitro</i> Susceptibility Rates over 32 years.</p

<i>In Vitro</i> Susceptibility Rates of different pathogens to empiric initial intraperitoneal therapies in period 2 (1993–2003).

<p>MSSA, methicillin-sensitive <i>S</i>. <i>aureus</i>; MRSA, methicillin-resistant <i>S</i>. <i>aureus</i>; CNS, coagulase-negative staphylococci; MRSE, methicillin-resistant Staphylococcus epidermidis; NA, not available; NT, not tested;</p><p>^a one vancomycin resistant enterococcus (VRE);</p><p>^b Bacteroides spp.; variables are expressed in number of antibiograms (percentage in parentheses regarding Susceptibility Rate);</p><p><i>In Vitro</i> Susceptibility Rates of different pathogens to empiric initial intraperitoneal therapies in period 2 (1993–2003).</p

Etiologic Spectrum of three different Peritonitis Episodes over 32 years.

<p>Distribution of organisms in period 1 (1979–1992), period 2 (1993–2003) and period 3 (2004–2014); all variables are expressed as percentage; Abbreviation: MSSA, methicillin-sensitive <i>Staphylococcus aureus</i>; MRSA, methicillin-resistant <i>Staphylococcus aureus</i>; CNS, coagulase-negative staphylococci; MRSE, methicillin-resistant <i>Staphylococcus epidermidis</i>.</p

Patient clinical data prior to and on PD.

<p>Patient clinical data prior to and on PD.</p

Characteristics of pre-developed TaqMan reagents.

<p>Characteristics of pre-developed TaqMan reagents.</p

(A.) CD46, CD55, and CD59 expression in patients on PD based on their history of peritonitis. (B.) Correlation of PD duration and RNA expression of CD46, CD55, and CD59 in patients on PD.

<p>(A.) RNA samples from patients with history of peritonitis (n = 11) and patients without history of peritonitis (n = 13) were analyzed for CD46, CD55, and CD59 by RT-PCR. The mean fold inductions of CD46, CD55, and CD59 were normalized to the housekeeping gene 18SrRNA. There were no significant differences comparing patients with history of PD-associated peritonitis with patients without history of PD-associated peritonitis. (B.) There was no statistically significant correlation between PD duration and the expression of CD46, CD55, or CD55 in patients on PD.</p

IHC of human peritoneal biopsies.

<p>(A.) CD46 staining was strong in mesothelial cells along the peritoneal surface in uremic controls and PD patients. (B.) CD55 was strongly positive in mesothelial cells along the peritoneal surface and in vessels in sub-peritoneal tissues in all groups. (C.) Intensive CD59 staining was observed in mesothelial cells in all groups. Vessels were positive for CD59 in uremic controls and PD patients. All images were taken at 400x.</p

Expression of CD46, CD55 and CD59 using IHC of biopsies from uremic controls (uremic patients at catheter implantation) and patients on peritoneal dialysis (PD).

<p><b>Expression was semiquantitative scored. PD patients were grouped according the D/P ratio creatinine and the D/D0 glucose in patients with low or low average peritoneal transport status (L/LA group) and patients with high average or high transport status (HA/H group)</b>. (A.) No statistically significant difference of CD46 staining between the groups was observed. (B.) CD55 staining was statistically significant decreased between the H/HA and the L/LA group and between the H/HA group and the uremic controls. No statistically significant differences between the L/LA group and the uremic controls could be observed. (C.) CD59 staining did not differ statistically significant between the groups.</p